MiMedx Group, Inc - Common Stock (MDXG)

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Cantor Fitzgerald has initiated coverage on MIMEDX, highlighting its strong market presence in wound care and surgical recovery. Targeting a $3.9 billion market, MIMEDX products demonstrate a 97% wound closure rate for diabetic foot ulcers, cost-effectiveness, and significant growth potential.

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.

MDXG stock results show that MiMedx Group beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy.

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday.

Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is likely to report earnings for its third quarter.

U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.